Skip to main content

Market Overview

Trevena's TRV027 Included In Global COVID-19 Study

Trevena's TRV027 Included In Global COVID-19 Study
  • Trevena Inc (NASDAQ: TRVN) has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase 2-Phase 3 trial in COVID-19 patients.
  • The trial is being conducted and funded as part of REMAP-CAP, a global network of clinicians, institutions, and research facilities to evaluate treatments with the potential to reduce mortality, ICU use, and morbidity in severely ill patients with COVID-19. 
  • Four active treatments are included in the study protocol, including TRV027, with 200-300 patients expected to be enrolled in each arm. TRV027 will be administered in conjunction with an ACE inhibitor.
  • The primary outcome is a composite of in-hospital mortality and provision of organ failure support while admitted to an ICU in the 21 days following randomization.
  • The trial is also evaluating clinical outcomes, including ICU and hospital length of stay, ventilator-free days, and organ failure-free days.
  • Price Action: TRVN shares are up 2.94% at $1.75 in the premarket session on the last check Wednesday.

Related Articles (TRVN)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19Biotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at